Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification
Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the CNS and/or the eye, wherein the composition is designed to be administered outside the blood-CNS and the blood-retina barriers. Furthermore, methods are provided for identifying and obtaining nucleic acid molecules encoding polypeptides involved in CNS disorders or of the eye, methods for diagnosing said disorders as well as transgenic animal deficient in the expression of target genes identified in accordance with the described method. In addition, methods of identifying and isolating drugs that are particularly useful for the treatment of disorders related to the CNS and/or the eye are disclosed.
1. A method for the treatment of wet age-related macular degeneration or diabetic retinopathy comprising administering to a subject who has been diagnosed with wet age-related macular degeneration or diabetic retinopathy a composition comprising a RNA compound comprising a double stranded region of RNA in a therapeutically effective amount to reduce levels of a target mRNA,
wherein said composition is administered outside the blood-retina barrier and the composition crosses the blood-retina barrier and reduces levels of the target mRNA inside the blood-retina barrier and treats the wet age-related macular degeneration or diabetic retinopathy of the subject who has been diagnosed with wet age-related macular degeneration or diabetic retinopathy,
wherein said double stranded region is 21-23 nucleotides in length.
2. The method of claim 1 , wherein the target mRNA is in the retina.
3. The method of claim 1 , wherein the target mRNA level is reduced in the inner segment of the eye ball.
4. The method of claim 1 , wherein the composition is applied outside the retinal region of the eye of the blood-retina barrier and crosses the blood-retina barrier to reduce the levels of the target mRNA in the retinal region of the eye.
5. The method of claim 1 , wherein the double stranded region of RNA contains a terminal 3′-hydroxyl group.
6. The method of claim 1 , wherein the nucleic acid molecule comprises an analogue of naturally occurring RNA.
7. The method or use of claim 6 , wherein the nucleotide sequence of the nucleic acid molecule differs from the nucleotide sequence of said target mRNA by addition, deletion, substitution or modification of one or more nucleotides.
8. The method of claim 1 , wherein the composition is administered systemically or by iontophoresis.
9. The method of claim 1 , wherein the composition is administered as a retrobulbar application or as eye drops.